Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database

Abstract Aim To describe the utilization of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and changes in clinical characteristics before and after GLP‐1 RA initiation in patients with type 2 diabetes (T2D) by chronic kidney disease (CKD) stage. Materials and Methods In this retrospective descriptive study using a nationwide electronic medical records database in Japan, we included patients with GLP‐1 RA prescriptions from June 2010 to October 2019. Clinical characteristics at GLP‐1 RA initiation, persistence proportion, and changes in clinical measurements after GLP‐1 RA initiation were described for all patients and by CKD stage, defined by baseline estimated glomerular filtration rate (eGFR). Results We included 8049 patients. During the study period, the proportion of patients with T2D initiating GLP‐1 RAs increased from 1.5% in 2010 to 3.3% in 2019. Also, the mean (95% confidence interval) of baseline age and eGFR ranged from 58.6 (56.7‐60.4) to 66.3 (65.5‐67.2) years and from 72.9 (68.0‐77.9) to 64.0 (62.2‐65.8) mL/min/1.73m 2 , respectively. The persistence proportion at 12 months was 49.5% overall, 37.8% in T2D patients with CKD with a baseline eGFR of less than 30 mL/min/1.73m 2 , and 34.6% in those undergoing dialysis. The rate of deterioration in renal function reduced after GLP‐1 RA initiation. Conclusions The utilization of GLP‐1 RAs has been increasing over the past decade, and GLP‐1 RAs have been used in patients with limited treatment options, such as the elderly or those with CKD. In T2D patients with CKD, the persistence proportion of GLP‐1 RAs was not low, and the renal dysfunction may be moderated by GLP‐1 RA initiation.